yes
and keeping in mind ... low/medium/ high disease burden patients to facilitate cross - comparison, AND MAJORITY having undergone TWO PRIOR lines of THERAPY
This could become standard of care.
that sample is very wide so the results cannot be ignored.
and the patients have had no or very little help from prior therapies.
thank god they now have/ or will have TLX 591 !!!
Ann: ProstACT SELECT Study of TLX591 rADC Therapy - Positive rPFS, page-13
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$22.90 |
Change
-0.010(0.04%) |
Mkt cap ! $7.664B | |||
| Open | High | Low | Value | Volume |
| $23.00 | $23.19 | $22.40 | $16.31M | 715.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 3391 | $22.89 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $22.93 | 2866 | 2 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| TLX (ASX) Chart |